Sun's anti-IL23 mAb meets in Phase III psoriasis trials

Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA) said anti-IL-23 antibody tildrakizumab ( MK-3222) met the co-primary endpoints in two Phase III trials to treat moderate to severe plaque psoriasis. The molecule is specific for the p19 subunit of IL-23 (IL-23p19).

In both studies, 100 and 200 mg doses of tildrakizumab significantly improved PASI 75 response rates and the proportion of patients with a score of 0 or 1 on the Physician's Global Assessment (PGA) of psoriasis at week 12 vs. placebo. On the latter endpoint, patients also had to have at least a two-point reduction from baseline on the seven-point scale, where 0 indicates clear skin. ...